Skip to main content
. 2023 Apr 13;7(14):3725–3734. doi: 10.1182/bloodadvances.2022009478

Figure 2.

Figure 2.

MC and impending or established secondary GF stratified based on day 0 alemtuzumab levels. (A) Cumulative incidence of MC, defined as donor chimerism <95%. (B) Cumulative incidence of impending or established secondary GF. Stratification using the first quartile day 0 alemtuzumab levels (level ≤ 0.32 μg/mL). D0, day 0.